Overview

Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis

Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
To investigate the long-term efficacy and safety of FK506 ophthalmic suspension in patients with vernal keratoconjunctivitis
Phase:
Phase 3
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Tacrolimus